WaFd (WAFD) Q4 2026 Earnings Call Transcript

WaFd reported fiscal 2026 net income of $241.2 million, its second-highest annual result, and full-year diluted EPS of $3.21 versus $2.63 in fiscal 2025; Q4 EPS was $0.76 versus $0.72 a year earlier. Q4 included $6.2 million of EverBank merger costs and $39.2 million of net charge-offs, including a significant $54 million C&I relationship, while nonperforming assets fell to $86 million from $136 million and NIM held at 2.81%. Management expects modest margin expansion over the next one to two quarters and targets EverBank merger closing in Q1 2027, with 29% EPS accretion after full cost savings; the deal remains subject to approvals, and management noted WaFd shares had fallen 18.9% since announcement versus an 8.3% decline in the Nasdaq Regional Bank Index.

Analysis

WAFD’s asset sales are a balance-sheet reset, not yet proof of durable earnings growth. Replacing low-coupon loans can lift portfolio yield, but lower balances pressure net interest income unless reinvestment or liability reduction offsets the runoff. The one-time sale gains also pull forward purchase-accounting accretion; neither should be capitalized as a recurring earnings run rate. The key near-term test is whether margin expansion actually offsets the smaller earning-asset base while deposit costs continue to reset.

The merger’s diversification case is plausible but not automatic: WaFd’s CRE exposure and EverBank’s NDFI focus may diversify reported concentrations, yet nonbank borrowers can share funding and liquidity vulnerabilities in a stress. The advertised accretion and returns depend on execution, cost saves, and balance-sheet marks—not simply closing. At 1–3 months, the proxy and regulatory path should clarify dilution, credit marks, and achievable savings. Over 6–18 months, integration costs, deposit retention, and NDFI credit performance will determine whether scale improves returns or adds complexity.

The market’s deal discount may be excessive if the economics hold, but no valuation or updated deal terms are provided to establish upside. Credit normalization is also less convincing than headline quarter-over-quarter improvement: resolution of one large exposure can improve aggregate metrics while underlying criticized-loan risk remains. Falsifiers include merger delays or weaker proxy economics, continued deposit-cost pressure that prevents margin gains, or renewed deterioration in criticized loans and delinquencies.

Key Decisions for Investors

• Do not chase headline EPS or the loan-sale gain. Monitor the next quarter’s net interest margin alongside earning-asset balances and deposit costs; a flat or lower margin despite asset repricing would weaken the reset thesis.
• Keep WAFD as a catalyst watch through the proxy and regulatory review rather than initiate an outright merger-arbitrage position without exchange terms and updated capital-impact detail. If deal economics weaken or approval timing slips, consider a modest short WAFD/long KRE relative-value hedge; upside risk is a clean approval path and credible cost-save execution.
• Track criticized loans, delinquencies, and remaining large nonaccrual credits separately from the resolved C&I relationship. A renewed sequential increase would challenge management’s normalization case and could outweigh merger-driven multiple support.